The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Novel therapies on the horizon for CTCL
Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, shares his views on the future treatment landscape for cutaneous T-cell lymphoma (CTCL), highlighting the upcoming MOGAT trial (NCT04128072) of mogamulizumab in combination with total skin electron bean therapy (TSEB) in patients with stage IB-IIB CTCL. Prof. Romero also comment on novel therapies being explored for CTCL including ASTX660 and lacutamab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
